NASDAQ · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · SMALL CAP
Cellyan Biotechnology Co. Ltd. HKPD
3 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$20.3M
▲ 21.7% vs FY2023
EPS · FY24
$-0.00
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-0.6%
Net margin · FY24
-0.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 20.3M
Revenue, FY2024 · full 3-year series below
Revenue
Net income
The company lost 0 cents on every revenue dollar this year.
Per share
USD -0.00
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-0.6%
Return on equity, FY2024
ROE
Operating margin-11.2%
Net margin-0.1%
Return on assets-0.3%
Each USD of equity lost 1 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 9.4M
total assets, end of FY2024
Total assetsUSD 9.4M
EquityUSD 5.0M
CashUSD 748,721.00
Gross debtUSD 1.9M
Net debtUSD 1.1M
Current ratio2.99×
Net debt stands at 23% of equity.
History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
Revenue $B
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
Net income $B
−0.0
0.0
0.0
EPS, diluted $
−0.00
0.18
0.15
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
−0.6
31.3
·
Shares out B
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
10 of 10
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed